Huntington's Disease clinical trials at UCSD
4 in progress, 2 open to eligible people
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
open to eligible people ages 18 years and up
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
San Diego, California and other locations
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
open to eligible people ages 25-60
For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.
La Jolla, California and other locations
PTC518 in Participants With Huntington's Disease (HD)
Sorry, in progress, not accepting new patients
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
La Jolla, California and other locations
Pridopidine Expanded Access Program
Sorry, not accepting new patients
Protocol PL101-HD501: This is an open-label post-trial expanded access program to provide continued treatment with pridopidine for individuals who completed the PROOF-HD study (PL101-HD301) as well as include treatment naïve HD patients ineligible for clinical trials. Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
La Jolla, California and other locations
Our lead scientists for Huntington's Disease research studies include Jody Corey-Bloom.
Last updated: